T raditionally, rapid point-of-care detection of influenza A virus (FluA) and influenza B virus (FluB) and respiratory syncytial viruses (RSV) has been performed using antigen immunoassays, which have low sensitivity (1, 2, 3) . In comparison, nucleic acid amplification tests (NAAT) have improved sensitivity but increased time to result (4) . Recently, several NAAT that provide results in Ͻ2 h and require little hands-on time have become commercially available. The U.S. Food and Drug Administration (FDA)-cleared Simplexa Flu A/B & RSV Direct assay (Focus Diagnostics, Cypress, CA) is a real-time reverse transcription (RT)-PCR system that detects FluA, FluB, and RSV in about 1 h from nasopharyngeal swabs that do not require nucleic acid extraction. The assay consists of the Simplexa Flu A/B & RSV Direct reagents, a 3 M Integrated Cycler, and direct amplification discs.
We compared the results of the Simplexa Direct assay to those of well-characterized laboratory-developed real-time RT-PCR tests (LDTs) for 498 prospectively collected nasopharyngeal swabs at the University of Washington Molecular Virology Laboratory during the 2013 peak influenza season in Seattle, WA (2 January to 9 February). The median patient age was 48 years (range, 16 days to 96 years); 90% of the subjects were Ն21 years of age. Samples with discordant Simplexa Direct and LDT results and a subset of samples with concordant negative results were tested by the Prodesse ProFluϩ assay (Hologic Gen-Probe, San Diego, CA). The Simplexa Direct and Prodesse assays were performed according to the manufacturers' protocols. For Simplexa Direct, 50 l of reaction mix from a single-use tube was added to the reagent well on one wedge of an 8-wedge amplification disc, 50 l of sample was added to the sample well, the wedge was covered, the disc was placed on the cycler, and the run was started. Each run could accommodate up to eight samples. Results for FluA, FluB, RSV, and an internal amplification control were provided as positive or negative and as PCR cycle threshold (C T ) values. Samples with uninterpretable amplification plots and viral target-negative samples that were negative for the internal amplification control were reported as invalid. RNA extraction and LDTs were carried out as previously described (5, 6) .
The reproducibility of Simplexa Direct was assessed by calculating the coefficients of variation (CVs) of C T values obtained for a panel of 8 clinical nasopharyngeal swabs (two negative samples and one sample positive for high and low concentrations of FluA, FluB, and RSV). Samples were divided into aliquots and tested eight times on different days by different technicians. The sensitivity of Simplexa Direct was compared to that of LDTs by testing 10-fold serial dilutions of positive clinical samples by both assays.
FluA was detected in 121 samples by LDTs and 112 by Simplexa Direct; FluB was detected in 11 samples by LDTs and 16 by Simplexa Direct; RSV was detected in 40 samples by LDTs and 36 by Simplexa Direct (Table 1) . The overall concordance rates for the two methods (excluding invalid results) were 96.6% (476/493; ϭ 0.91), 97.6% (481/493; ϭ 0.47), and 99.2% (488/492; ϭ 0.94) for FluA, FluB, and RSV, respectively. Positive percentages of agreement were 86.4%, 36.8%, and 89.7% for FluA, FluB, and RSV, respectively. Simplexa Direct, LDT, and Prodesse results for 37 samples with discrepant Simplexa Direct and LDT results are shown in Table 2 . Of these, 27 had Simplexa Direct or LDT C T values Ͼ 35, indicating viral copy numbers near the assay limits of detection. The low FluB kappa value and positive percent agreement were due to nine Simplexa Direct-positive/LDT-negative samples that were likely false-positive results, which may have been caused by a malfunctioning Integrated Cycler. All nine were FluB negative by the Prodesse assay and FluA positive by all three methods. Six of 22 LDT-positive/Simplexa Direct-negative samples were positive by the Prodesse assay, while 1 of 14 Simplexa Directpositive/LDT-negative samples was positive by Prodesse. Forty concordant negative samples were negative by Prodesse. Eleven samples (2.8%) required repeat testing due to invalid results by Simplexa Direct; five were invalid after repeat testing. All samples had valid results by LDTs, which identified two positive samples among the five with final invalid Simplexa Direct results ( Table 2) .
The reproducibility of the Simplexa Direct assay was good, The Simplexa Direct assay performed well compared with our established LDTs, demonstrating no significant differences in detection of FluA, FluB, and RSV in clinical specimens. Samples with discordant results were most likely due to low viral loads near the assay limits of detection. Our study was limited by the fact that samples were tested sequentially by Simplexa Direct, LDTs, and Prodesse, with sample freeze/thaw cycles between each test. This may have caused an underestimation of assay concordance due to loss of viral RNA in subsequent tests. A higher-than-expected proportion of samples (2.8%) had invalid Simplexa Direct results, including two that were positive for RSV by LDTs and Prodesse. All samples tested were nasopharyngeal samples collected in Universal Transport Medium, which is the FDA-approved sample type.
This study was the first comparison of LDTs to the newly developed Simplexa FluA/B & RSV Direct assay that provides results directly from specimens in about 1 h. A study that compared the Nanosphere Verigene RVϩ assay to the Simplexa Flu A/B & RSV assay, which requires nucleic acid extraction and conventional real-time PCR, reported Simplexa sensitivities for FluA, FluB, and RSV of 82.8%, 76.2%, and 94.6%, respectively (7). A study comparing LDT to the same Simplexa Flu A/B & RSV assay with a modified protocol that eliminated nucleic acid extraction but used the conventional real-time PCR format reported overall sensitivities of 95.1% and 99.6 (8) .
Compared to LDTs, the Simplexa Flu A/B and RSV Direct assays showed good performance. Advantages over LDTs include rapid speed and ease of use. Simplexa Direct will provide accurate results to patients more quickly than LDTs, allowing more-rapid antiviral treatment and patient management. 
